Evidence map›Paper›PMID 34690038›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2022

Corrigendum to 'Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study' [European Journal of Cancer 154 (2021) 246-252].

Nicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, Anna La Salvia, Johannes Hofland, Jorge Hernando, Mohamad B Sonbol, Rocio Garcia-Carbonero, Jaume Capdevila, Wouter W de Herder and 11 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Nicola FazioDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy. Electronic address: nicola.fazio@ieo.it.
Lorenzo GervasoDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy; Molecular Medicine Program, University of Pavia, Pavia, Italy.
Thorvardur R HalfdanarsonDivision of Medical Oncology Mayo Clinic, Rochester, MN, USA.
Anna La SalviaMedical Oncology Department, Hospital Universitario Doce de Octubre, Imas12, UCM, Madrid, Spain.
Johannes HoflandDepartment of Internal Medicine, Sector Endocrinology, Rotterdam, the Netherlands.
Jorge HernandoVall Hebron University Hospital and Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Mohamad B SonbolDepartment of Hematology and Oncology Mayo Clinic, Phoenix, AZ, USA.
Rocio Garcia-CarboneroMedical Oncology Department, Hospital Universitario Doce de Octubre, Imas12, UCM, Madrid, Spain.
Jaume CapdevilaVall Hebron University Hospital and Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Wouter W de HerderDepartment of Internal Medicine, Sector Endocrinology, Rotterdam, the Netherlands.
Anna KoumarianouHematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Gregory Kaltsas1st Department of Propaedeutic Internal Medicine, Endocrine Unit, National and Kapodistrian, University of Athens, Athens, 11527, Greece.
Maura RossiOncology Unit and Centro Documentazione Osteonecrosi, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Simona Grozinsky-GlasbergNeuroendocrine Tumors Unit, ENETS Center of Excellence, Department of Endocrinology and Metabolism Service, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Kira OleinikovNeuroendocrine Tumors Unit, ENETS Center of Excellence, Department of Endocrinology and Metabolism Service, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Sabrina BoselliData Management-Clinical Trial Office. Scientific Direction. European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Darina TamayoData Management-Clinical Trial Office. Scientific Direction. European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Vincenzo BagnardiDepartment of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
Alice LaffiDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Manila RubinoDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Francesca SpadaDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34690038
PMCPMC8529581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.